Hepcludex (Bulevirtide)

Hepcludex is indicated for patients with chronic hepatitis D virus (HDV) infection, typically in combination with nucleos(t)ide analogues for hepatitis B virus suppression.

• Used to treat adults with confirmed chronic HDV infection.
• Administered as a subcutaneous injection, usually once daily or as prescribed.
• May be considered for patients who have not responded adequately to standard hepatitis B therapy.
• Intended for use under specialist supervision in hepatology or infectious disease settings.
• Can be part of a comprehensive antiviral regimen targeting both HBV and HDV.

The safety profile of Hepcludex includes a range of observed adverse events, which are categorized by frequency and severity.

Common

• Injection site reactions such as pain, redness, swelling, or induration lasting up to several days.
• Mild headache or fatigue that usually resolves without intervention.
• Transient elevation of liver enzymes (ALT/AST) observed during early treatment phases.
• Nausea, mild abdominal discomfort, or loss of appetite that are generally self‑limited.

Serious

• Severe allergic reactions, including anaphylaxis, characterized by rash, swelling, respiratory distress, or hypotension.
• Significant liver injury or hepatitis flare, indicated by marked increases in ALT/AST and bilirubin.
• Persistent or worsening thrombocytopenia that may require clinical monitoring.

Before initiating Hepcludex, clinicians should evaluate several precautionary factors to ensure safe use.

• Assess baseline liver function tests and monitor regularly throughout therapy.
• Evaluate for a history of hypersensitivity to bulevirtide or any component of the formulation.
• Use caution in patients with pre‑existing liver disease or decompensated cirrhosis.
• Pregnancy status should be determined; the drug’s safety in pregnancy is not established.
• Counsel patients on proper subcutaneous injection technique to minimize local reactions.
• Consider renal function, although bulevirtide is not primarily renally excreted.
• Review concomitant antiviral regimens to avoid overlapping toxicities.

Hepcludex may interact with other medicines; understanding potential interactions helps optimize treatment outcomes.

Avoid

• Co‑administration with other viral entry inhibitors that target the same NTCP pathway.
• Concurrent use of drugs known to cause severe hypersensitivity reactions.

Use with caution

• Nucleos(t)ide analogues for hepatitis B, as combined therapy may affect liver enzyme levels.
• Immunosuppressive agents, which could alter the immune response to viral infection.
• Medications metabolized by hepatic pathways that may be influenced by changes in liver function.
• Herbal supplements that affect liver enzymes, such as St John’s wort.